The clinical information you need, at your fingertips.

AAN and AHS incorporate CGRP-targeted therapies and other newer options into their first migraine prevention update since 2012. . .

A randomized trial found catheter-directed thrombolysis sharply lowered early complications in higher-risk PE versus anticoagulation alone. . .

Bixlenvo combines two previously approved antiretrovirals in a once-daily option for virologically suppressed adults. . .

Prespecified VESALIUS-CV findings suggest intensive LDL-C lowering may improve survival in high-risk patients without prior MI or stroke. . .

The STAREE trial found fewer major cardiovascular events, but no extension of disability-free survival, in healthy older adults. . .

Once-daily therapy improved muscle, skin, and physical function measures while supporting corticosteroid tapering. . .